India Tops China As Preferred Site Of Outsourced Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
India has surpassed China as the country preferred by foreign drug makers for conducting clinical trials. India's Planning Commission says the country received 139 new trials over a recent period when China received 98. The commission said the outsourced trials are worth about $300 million to the country and the amount is expected to grow to as much as $2 billion within two years. The same report noted, however, that India is short 30,000 to 50,000 research personnel needed to carry out the trials. (Click here for more
India has surpassed China as the country preferred by foreign drug makers for conducting clinical trials. India's Planning Commission says the country received 139 new trials over a recent period when China received 98. The commission said the outsourced trials are worth about $300 million to the country and the amount is expected to grow to as much as $2 billion within two years. The same report noted, however, that India is short 30,000 to 50,000 research personnel needed to carry out the trials. (Click here for more) "India Overtakes China As No. 1 Destination For Clinical Trials" - Times of India (4/5/08) |